search
Back to results

PCC and Fibrinogen Compared With FFP in PPH

Primary Purpose

Postpartum Haemorrhage

Status
Withdrawn
Phase
Phase 4
Locations
Finland
Study Type
Interventional
Intervention
PCC
FFP
Sponsored by
Helsinki University Central Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postpartum Haemorrhage

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

Women who have delivered vaginally or by caesarean section with a PPH of 2000 ml (the amount of blood loss: in addition to the suctioned blood, sponges, wraps, swabs, etc. are carefully weighed)

Exclusion Criteria:

Women with a history of bleeding tendency or hepatic or renal insufficiency, or PPH exceeding 3000 ml because in that case the initial need for fibrinogen may be even more

Sites / Locations

  • Maternity Hospital, Helsinki University Central Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

PCC group

FFP group

Arm Description

Twenty patients in the PCC group receive 15 IU/kg of Octaplex concentrate and 2 g of Riastap concentrate. Additional fibrinogen is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm.

Twenty patients in the FFP group receive 4 units of FFP (Octaplas). Additional fibrinogen (Riastab) is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm. The fibrinogen content of the FFP will be taken into consideration (2.1 g in 4 units of FFP).

Outcomes

Primary Outcome Measures

Blood loss
The suctioned blood is recorded and sponges, wraps, swabs, etc. are carefully weighed. The amount of blood loss will be compared between the groups.

Secondary Outcome Measures

Maximum clot firmness (MCF)
INTEM, EXTEM, FIBTEM and APTEM / ROTEM
Endogenous thrombin potential
CAT
Fibrinogen level
Clauss method
Platelet function
PFA-100
Clotting time (CT)
INTEM, EXTEM, FIBTEM and APTEM / ROTEM
Clot formation time (CFT)
INTEM, EXTEM, FIBTEM and APTEM / ROTEM

Full Information

First Posted
July 13, 2013
Last Updated
October 8, 2018
Sponsor
Helsinki University Central Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01910675
Brief Title
PCC and Fibrinogen Compared With FFP in PPH
Official Title
Use of Prothrombin Complex Concentrate and Fibrinogen Compared With Fresh Frozen Plasma (and Fibrinogen if Needed) in the Treatment of Postpartum Haemorrhage
Study Type
Interventional

2. Study Status

Record Verification Date
October 2018
Overall Recruitment Status
Withdrawn
Why Stopped
Impossible to get a written informed consent beforehand
Study Start Date
July 2013 (undefined)
Primary Completion Date
October 2018 (Anticipated)
Study Completion Date
October 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Helsinki University Central Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to find out if the regimen of prothrombin complex concentrate (PCC) together with fibrinogen concentrate is as efficient as fresh frozen plasma (FFP) (plus fibrinogen if needed) during the early stages of the transfusion therapy in postpartum haemorrhage (PPH). The original protocol included the use of HES and the recruitment of patients was postponed while waiting the final decision by EMA. All HES solutions were abandoned at our institution in September and an amendment was made to change the protocol. HES solution are replaced by the use of hyperoncotic (20%) albumin.
Detailed Description
Forty patients are randomized to receive either PCC and fibrinogen concentrate (PCC group) or FFP (and fibrinogen if needed) (FFP group), 20 patients in each group. Patients in the PCC group receive 15 IU/kg of PCC concentrate and 2 g of fibrinogen concentrate. Patients in the FFP group receive 4 units of FFP. In both groups, additional fibrinogen is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm. Baseline blood samples will be drawn at study inclusion when the (on-going) blood loss exceeds 1500 ml. The next samples will be drawn at 45 min (or immediately after the administration of the study drug if later). Otherwise, the management protocol strictly follows the local PPH guideline. The primary endpoint is the amount of blood loss within the first 6 and 24 hours after delivery. Secondary endpoints include the difference/similarity in the laboratory determinations (ia coagulation screen, PFA-100, CAT and ROTEM).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postpartum Haemorrhage

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PCC group
Arm Type
Experimental
Arm Description
Twenty patients in the PCC group receive 15 IU/kg of Octaplex concentrate and 2 g of Riastap concentrate. Additional fibrinogen is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm.
Arm Title
FFP group
Arm Type
Active Comparator
Arm Description
Twenty patients in the FFP group receive 4 units of FFP (Octaplas). Additional fibrinogen (Riastab) is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm. The fibrinogen content of the FFP will be taken into consideration (2.1 g in 4 units of FFP).
Intervention Type
Drug
Intervention Name(s)
PCC
Other Intervention Name(s)
Octaplex, Riastab
Intervention Description
15 IU/kg Octaplex and 2 g Riastab. Additional fibrinogen if needed.
Intervention Type
Drug
Intervention Name(s)
FFP
Other Intervention Name(s)
Octaplas
Intervention Description
4 units Octaplas. Additional fibrinogen if needed.
Primary Outcome Measure Information:
Title
Blood loss
Description
The suctioned blood is recorded and sponges, wraps, swabs, etc. are carefully weighed. The amount of blood loss will be compared between the groups.
Time Frame
Within the first 6 and 24 hours after delivery
Secondary Outcome Measure Information:
Title
Maximum clot firmness (MCF)
Description
INTEM, EXTEM, FIBTEM and APTEM / ROTEM
Time Frame
At the time when the blood loss exceeds 1500 ml and 45 min later
Title
Endogenous thrombin potential
Description
CAT
Time Frame
At the time when the blood loss exceeds 1500 ml and 45 min later
Title
Fibrinogen level
Description
Clauss method
Time Frame
At the time when the blood loss exceeds 1500 ml and 45 min later
Title
Platelet function
Description
PFA-100
Time Frame
At the time when the blood loss exceeds 1500 ml and 45 min later
Title
Clotting time (CT)
Description
INTEM, EXTEM, FIBTEM and APTEM / ROTEM
Time Frame
At the time when the blood loss exceeds 1500 ml and 45 min later
Title
Clot formation time (CFT)
Description
INTEM, EXTEM, FIBTEM and APTEM / ROTEM
Time Frame
At the time when the blood loss exceeds 1500 ml and 45 min later

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women who have delivered vaginally or by caesarean section with a PPH of 2000 ml (the amount of blood loss: in addition to the suctioned blood, sponges, wraps, swabs, etc. are carefully weighed) Exclusion Criteria: Women with a history of bleeding tendency or hepatic or renal insufficiency, or PPH exceeding 3000 ml because in that case the initial need for fibrinogen may be even more
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jouni V. Ahonen, Ph.D., M.D.
Organizational Affiliation
Maternity Hospital, Helsinki University Central Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maternity Hospital, Helsinki University Central Hospital
City
Helsinki
State/Province
Uusimaa
ZIP/Postal Code
FI-00610
Country
Finland

12. IPD Sharing Statement

Citations:
PubMed Identifier
21069897
Citation
Ahonen J, Stefanovic V, Lassila R. Management of post-partum haemorrhage. Acta Anaesthesiol Scand. 2010 Nov;54(10):1164-78. doi: 10.1111/j.1399-6576.2010.02309.x.
Results Reference
background

Learn more about this trial

PCC and Fibrinogen Compared With FFP in PPH

We'll reach out to this number within 24 hrs